ECSP21060917A - Formulación de anticuerpos terapéuticos - Google Patents

Formulación de anticuerpos terapéuticos

Info

Publication number
ECSP21060917A
ECSP21060917A ECSENADI202160917A ECDI202160917A ECSP21060917A EC SP21060917 A ECSP21060917 A EC SP21060917A EC SENADI202160917 A ECSENADI202160917 A EC SENADI202160917A EC DI202160917 A ECDI202160917 A EC DI202160917A EC SP21060917 A ECSP21060917 A EC SP21060917A
Authority
EC
Ecuador
Prior art keywords
therapeutic antibodies
formulation
pharmaceutical formulations
aqueous pharmaceutical
stable aqueous
Prior art date
Application number
ECSENADI202160917A
Other languages
English (en)
Inventor
Vincent John Corvari
Galen Huaiqiu Shi
Karthik Pisupati
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP21060917A publication Critical patent/ECSP21060917A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Formulaciones farmacéuticas acuosas estables para anticuerpos terapéuticos y métodos de uso de dichas formulaciones farmacéuticas acuosas estables.
ECSENADI202160917A 2019-02-18 2021-08-17 Formulación de anticuerpos terapéuticos ECSP21060917A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962807006P 2019-02-18 2019-02-18
US201962880846P 2019-07-31 2019-07-31
US201962947198P 2019-12-12 2019-12-12

Publications (1)

Publication Number Publication Date
ECSP21060917A true ECSP21060917A (es) 2021-09-30

Family

ID=72040829

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202160917A ECSP21060917A (es) 2019-02-18 2021-08-17 Formulación de anticuerpos terapéuticos

Country Status (21)

Country Link
US (2) US11634485B2 (es)
EP (1) EP3927729A4 (es)
JP (2) JP7266108B2 (es)
KR (1) KR102735988B1 (es)
CN (2) CN113474360B (es)
AU (2) AU2020225202B2 (es)
CL (1) CL2021002182A1 (es)
CO (1) CO2021010697A2 (es)
CR (1) CR20210435A (es)
DO (1) DOP2021000170A (es)
EC (1) ECSP21060917A (es)
IL (1) IL285134A (es)
JO (1) JOP20210229A1 (es)
MA (1) MA55033A (es)
MX (1) MX2021009851A (es)
NZ (1) NZ778977A (es)
PE (1) PE20212185A1 (es)
PH (1) PH12021551916A1 (es)
SG (1) SG11202108627SA (es)
UA (1) UA128098C2 (es)
WO (1) WO2020172002A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
CN113769082A (zh) * 2020-06-10 2021-12-10 上海君实生物医药科技股份有限公司 抗il-17a抗体药物组合物及其用途
AU2022205989A1 (en) * 2021-01-08 2023-07-27 Lanier Biotherapeutics, Inc. Neutralizing antibodies to il-17a, fusion proteins thereof, and uses thereof
JP2025539457A (ja) * 2022-12-01 2025-12-05 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 抗ｇｍ－ｃｓｆ抗体の液体医薬品製剤及びその用途
CN118184793A (zh) * 2022-12-12 2024-06-14 江苏康缘瑞翱生物医药科技有限公司 一种靶向TNF-α与IL-17A的双特异性融合蛋白及其用途
CN116874596B (zh) * 2023-09-06 2023-11-24 南京佰抗生物科技有限公司 抗S100β蛋白的单克隆抗体及其制备方法和应用
AU2024353756A1 (en) * 2023-09-27 2026-05-07 Samsung Bioepis Co., Ltd. Stable liquid formulation of anti-il-17 antibody
WO2025264037A1 (ko) * 2024-06-20 2025-12-26 (주)셀트리온 안정한 약제학적 제제

Family Cites Families (360)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
AU2002324556A1 (en) 2001-07-25 2003-02-17 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
AU2003230908A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
JP2006512102A (ja) 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
AU2011226771B2 (en) 2002-06-14 2012-10-04 Medimmune, Llc Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
NZ537610A (en) 2002-07-02 2006-07-28 Smithkline Beecham Corp Stable formulations of the C242 antibody
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7055598B2 (en) 2002-08-26 2006-06-06 Halliburton Energy Services, Inc. Fluid flow control device and method for use of same
WO2004019860A2 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
WO2004060343A1 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
US20040208869A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
US7374762B2 (en) 2003-05-14 2008-05-20 Immunogen, Inc. Drug conjugate composition
PT2272868E (pt) 2003-06-05 2015-07-07 Genentech Inc Terapêutica de combinação para distúrbios de células b
TR201903984T4 (tr) 2003-08-12 2019-04-22 Lilly Co Eli Mekanik avantaja yönelik üçlü vida dişine sahip ilaç dağıtım aparatı.
US8496930B2 (en) 2003-10-01 2013-07-30 Kyowa Hakko Kirin Co., Ltd Method of stabilizing antibody and stabilized solution-type antibody preparation
PE20050928A1 (es) 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
WO2005065709A2 (de) 2003-12-24 2005-07-21 Boehringer Ingelheim International Gmbh Gefriergetrocknete formulierung von antikörperkonjugaten
EP1712240B1 (en) 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
PT1732629T (pt) 2004-03-30 2019-06-07 Lilly Co Eli Aparelho de dispensação de medicamento com uma característica de bloqueio acionada por mola ativada por administração de dose final
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006071441A2 (en) 2004-11-30 2006-07-06 Curagen Corporation Antibodies directed to gpnmb and uses thereof
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
ES2407468T3 (es) 2005-04-18 2013-06-12 Yeda Research And Development Company Limited Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
WO2006138181A2 (en) * 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
AU2006259536A1 (en) 2005-06-15 2006-12-28 Schering Corporation Anti-IGF1R antibody formulations
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
AU2006295340B2 (en) 2005-08-05 2010-11-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
DOP2005000210A (es) 2005-10-19 2006-04-30 Genentech Inc Antibony formulations
US20070172520A1 (en) 2005-11-18 2007-07-26 University Of South Florida Immunotargeting of Nonionic Surfactant Vesicles
KR20080071192A (ko) 2005-11-22 2008-08-01 와이어쓰 면역글로불린 융합 단백질 제형
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
JP5405122B2 (ja) 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
RS55963B1 (sr) 2005-12-29 2017-09-29 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, metode i upotrebe
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
EP1987067A4 (en) 2006-02-15 2012-01-25 Imclone Llc ANTIBODY FORMULATION
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
JP2009534390A (ja) 2006-04-21 2009-09-24 アムジェン インコーポレイテッド 生物医薬品製剤のための緩衝剤
AU2007260769A1 (en) 2006-06-14 2007-12-21 Imclone Llc Lyophilized formulations of anti-EGFR antibodies
JPWO2008029908A1 (ja) 2006-09-07 2010-01-21 協和発酵キリン株式会社 抗体を含有する安定な凍結乾燥医薬製剤
AU2007300221A1 (en) 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
EP2081553B1 (en) 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
JP5623743B2 (ja) 2006-10-20 2014-11-12 アムジエン・インコーポレーテツド 安定なポリペプチド製剤
DE102006053375A1 (de) 2006-11-10 2008-05-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Mischung von Pulvern
CN101553504A (zh) 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
MX2009006594A (es) 2006-12-21 2009-08-12 Amgen Inc Formulaciones de ph regulado y estables que contienen polipeptidos.
WO2008086395A2 (en) 2007-01-09 2008-07-17 Wyeth Anti-il-13 antibody formulations and uses thereof
US20100189723A1 (en) 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
MX2009010179A (es) 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
US20100209434A1 (en) 2007-03-30 2010-08-19 Medimmune, Llc Antibody formulation
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
AR067010A1 (es) * 2007-06-14 2009-09-30 Elan Pharm Inc Formulaciones de inmunoglobulina liofilizadas y metodos para su preparacion
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
WO2009070642A1 (en) 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
WO2009120684A1 (en) 2008-03-25 2009-10-01 Medimmune, Llc Antibody formulation
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20090324586A1 (en) 2008-06-26 2009-12-31 Wyeth Lyophilization cycle robustness strategy
ES2968301T3 (es) 2008-08-05 2024-05-08 Wyeth Llc Liofilización por encima del colapso
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
BRPI0918419A2 (pt) 2008-09-19 2015-11-24 Hoffmann La Roche nova formulação anticorpo
CA2736864C (en) 2008-09-19 2020-10-13 Pfizer Inc. Stable liquid antibody formulation
US20110256149A1 (en) 2008-10-09 2011-10-20 Medimmune, Llc Antibody formulation
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
TW201032826A (en) 2008-11-17 2010-09-16 Genentech Inc Method and formulation for reducing aggregation of a macromolecule under physiological conditions
RU2011124527A (ru) 2008-11-17 2012-12-27 Дженентек, Инк. Способ и композиция для уменьшения агрегации макромолекулы в физиологических условиях
US20120027772A1 (en) 2008-11-20 2012-02-02 Genentech, Inc. Therapeutic protein formulations
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
MX2011005672A (es) 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
US20110236391A1 (en) * 2008-12-09 2011-09-29 Hanns-Christian Mahler Method for obtaining an excipient-free antibody solution
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
TW201613969A (en) * 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
WO2010100135A1 (en) 2009-03-05 2010-09-10 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
RU2011140486A (ru) 2009-03-06 2013-04-20 МЕДИММЬЮН, ЭлЭлСи Композиции, содержащие гуманизированные антитела к cd19
EP2439533B1 (en) 2009-03-31 2017-08-02 DENKA SEIKEN Co., Ltd. Immunoassay method and reagent therefor
JP2010241718A (ja) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd 安定な抗体の水溶液製剤
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
CA2764180A1 (en) 2009-06-18 2010-12-23 Wyeth Llc Lyophilized formulations for small modular immunopharmaceuticals
WO2010148321A1 (en) 2009-06-18 2010-12-23 Wyeth Llc Slow dissolution method for reconstitution of lyophilized material
EP2453874A2 (en) 2009-07-14 2012-05-23 Biogen Idec MA Inc. Methods for inhibiting yellow color and peroxide formation in a composition
EP2458990B1 (en) 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20110059079A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
BR112012012080B1 (pt) 2009-11-20 2022-11-29 Biocon Limited Formulações de histidina-trealose do anticorpo t1h
CN102686241A (zh) 2009-12-29 2012-09-19 霍夫曼-拉罗奇有限公司 抗体配制剂
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SI3295957T1 (sl) 2010-01-15 2020-02-28 Kirin-Amgen, Inc. Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice
BR112012022223B1 (pt) 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
ES2484266T3 (es) 2010-03-01 2014-08-11 Eli Lilly And Company Dispositivo de inyección automático con mecanismo de retardo incluyendo un elemento de empuje de función doble
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
EP2547365A1 (en) 2010-03-17 2013-01-23 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
WO2011141926A2 (en) 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
AU2011274363A1 (en) 2010-07-02 2013-01-24 Medimmune, Llc Antibody formulations
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
FR2962650B1 (fr) 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
CA2811009A1 (en) 2010-09-17 2012-03-22 Abbvie Inc. Raman spectroscopy for bioprocess operations
CN106267189B (zh) 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
TWI616204B (zh) 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
CN103458926B (zh) 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
EP2500035A1 (en) 2011-03-15 2012-09-19 Icon Genetics GmbH Pharmaceutical formulation containing immunglobulin
TWI719112B (zh) 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
MX341076B (es) 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
TWI907924B (zh) 2011-05-02 2025-12-11 日商武田藥品工業股份有限公司 抗-α4β7抗體之調配物
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CA2853112C (en) 2011-10-25 2018-08-21 Onclave Therapeutics Limited Antibody formulations and methods
AR088579A1 (es) 2011-10-31 2014-06-18 Genentech Inc Formulaciones de anticuerpos
WO2013083497A1 (en) 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
US20130189218A1 (en) 2011-12-23 2013-07-25 Mersana Therapeutics, Inc. Pharmaceutical formulations for fumagillin derivative-phf conjugates
NZ627859A (en) 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
MX362191B (es) * 2012-03-07 2019-01-08 Lilly Co Eli Formulacion de anticuerpo il-17.
US10093728B2 (en) 2012-03-07 2018-10-09 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
CA2866624C (en) 2012-03-07 2022-06-28 Deka Products Limited Partnership Infusion pump assembly
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
PL2849723T3 (pl) 2012-05-18 2018-10-31 Genentech, Inc. Formulacje o wysokim stężeniu przeciwciał monoklonalnych
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US20150150982A1 (en) 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
EP2866833B1 (en) 2012-06-27 2019-05-15 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
US20140227250A1 (en) 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
MX2015003007A (es) * 2012-09-07 2015-06-05 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab.
CN104768578A (zh) 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
AU2013337644A1 (en) 2012-11-01 2015-05-07 Abbvie Inc. Stable Dual Variable Domain Immunoglobulin protein formulations
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EP2931311A4 (en) 2012-12-13 2016-08-17 Merck Sharp & Dohme LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
EP2934587A4 (en) 2012-12-18 2016-08-03 Merck Sharp & Dohme Liquid formulations for an anti-TNF-alpha-antibody
JP6400595B2 (ja) 2012-12-21 2018-10-03 グレンマーク ファーマシューティカルズ， エセ．アー． 抗ｈｅｒ２抗体製剤
JP2016513098A (ja) 2013-02-07 2016-05-12 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 癌の標的治療用抗体と抱合した極めて強力なプロドラック形態の２−ピロリノドキソルビシン（ｐ２ｐｄｏｘ）
CA2904713A1 (en) 2013-03-11 2014-10-09 Amgen Inc. Protein formulations comprising darbepoetin
CN105209069B (zh) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
SG11201506372RA (en) 2013-03-13 2015-09-29 Seattle Genetics Inc Cyclodextrin and antibody-drug conjugate formulations
JP2016515515A (ja) 2013-03-15 2016-05-30 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 抗プロラクチン受容体抗体製剤
JP6407174B2 (ja) 2013-03-15 2018-10-17 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 抗体の配合物および該配合物の使用
KR20220041957A (ko) 2013-03-15 2022-04-01 아비에 도이치란트 게엠베하 운트 콤파니 카게 항-egfr 항체 약물 접합체 제형
KR20150132332A (ko) 2013-03-15 2015-11-25 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 저농도 항체 제형
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
TWI679019B (zh) 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
US20160128944A1 (en) 2013-06-04 2016-05-12 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
DK3049441T3 (da) 2013-09-27 2020-02-03 Hoffmann La Roche Anti-PDL1-antistofformuleringer
CN113350278B (zh) 2013-10-24 2023-03-24 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
HRP20241036T1 (hr) 2013-11-21 2024-11-08 Genmab A/S Liofilizirana formulacija konjugata protutijelo-lijek
WO2015110930A1 (en) 2014-01-24 2015-07-30 Pfizer Inc. Modified interleukin 21 receptor proteins
US20150225479A1 (en) 2014-02-12 2015-08-13 Sanofi Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
US20150274819A1 (en) 2014-03-03 2015-10-01 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
WO2015138337A1 (en) 2014-03-09 2015-09-17 Abbvie, Inc. Compositions and methods for treating rheumatoid arthritis
EP3118210B1 (en) 2014-03-11 2019-11-13 Green Cross Holdings Corporation Method for purifying immunoglobulin
WO2015137530A1 (ko) 2014-03-11 2015-09-17 주식회사 녹십자홀딩스 면역글로불린의 정제방법
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
WO2015153514A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
JP6596014B2 (ja) 2014-03-31 2019-10-23 アムジェン ケー・エー，インコーポレイテッド 爪および頭皮乾癬の治療方法
EP3125928A4 (en) 2014-04-02 2017-11-29 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
US20170028062A1 (en) 2014-04-07 2017-02-02 Seattle Genetics, Inc. Stable formulations for anti-cd19 antibodies and antibody-drug conjugates
JP2015209384A (ja) 2014-04-24 2015-11-24 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 医薬製剤
CA2952609A1 (en) 2014-06-26 2015-12-30 Amgen Inc. Solid protein formulations comprising stabilizer, sugar alcohol, sugar and surfactant
EP3179985A1 (en) 2014-08-14 2017-06-21 Brown University Compositions for stabilizing and delivering proteins
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
AU2015310879A1 (en) 2014-09-03 2017-03-02 Medimmune Limited Stable anti-IL-4R-alpha antibody formulation
SG11201701821QA (en) 2014-09-15 2017-04-27 Genentech Inc Antibody formulations
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
MX2017004986A (es) 2014-10-17 2017-08-18 Amgen Inc Anticuerpos dirigidos a angiopoyetina-1 y angiopoyetina-2 para terapias oculares.
KR20170065662A (ko) 2014-10-18 2017-06-13 화이자 인코포레이티드 항-il-7r 항체 조성물
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3237000A1 (en) 2014-12-23 2017-11-01 Pfizer Inc Stable aqueous antibody formulation for anti tnf alpha antibodies
US20180000932A1 (en) 2014-12-31 2018-01-04 Novelmed Therapeutics, Inc. Formulation of aglycosylated therapeutic antibodies
AU2016210918A1 (en) 2015-01-28 2017-07-13 Pfizer Inc., Stable aqueous anti- vascular endothelial growth factor (VEGF) antibody formulation
PT3256154T (pt) 2015-02-09 2020-01-09 Ucb Biopharma Sprl Composição farmacêutica compreendendo um anticorpo
US20180008707A1 (en) 2015-02-13 2018-01-11 Sanofi Stable liquid formulation for monoclonal antibodies
MY188749A (en) 2015-04-17 2021-12-28 Bristol Myers Squibb Co Compositions comprising a combination of nivolumab and ipilimumab
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
US20180201673A1 (en) * 2015-07-16 2018-07-19 Eli Lilly And Company Treatment of pruritus
HRP20201297T1 (hr) 2015-08-19 2020-11-27 Astrazeneca Ab Stabilna formulacija anti-ifnar1
CN106474470B (zh) 2015-08-28 2020-05-22 江苏恒瑞医药股份有限公司 一种抗il-17a抗体的组合物
US10000561B2 (en) 2015-09-09 2018-06-19 Novartis Ag Thymic stromal lymphopoietin (TSLP)-binding molecules and methods of using the molecules
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
AU2016329034B2 (en) 2015-09-22 2019-05-23 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
MX395336B (es) 2015-09-28 2025-03-25 Suzhou Suncadia Biopharmaceuticals Co Ltd Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.
WO2017055966A1 (en) 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
CN106620690A (zh) 2015-10-30 2017-05-10 上海抗体药物国家工程研究中心有限公司 一种稳定的抗体制剂
MX2018005226A (es) 2015-10-30 2019-04-29 Genentech Inc Formulaciones de anticuerpo anti-factor d.
AU2016356717B2 (en) 2015-11-18 2022-09-29 Sio2 Medical Products, Inc. Pharmaceutical package for ophthalmic formulations
EP3383435A4 (en) 2015-11-30 2019-07-10 Medimmune, LLC OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
CN108367072B (zh) 2015-12-07 2022-12-27 默克专利股份有限公司 含抗-pd-l1抗体avelumab的水性药物制剂
CN109152831A (zh) 2015-12-29 2019-01-04 安口生物公司 贝伐珠单抗的缓冲制剂
CN108778261A (zh) 2016-01-12 2018-11-09 雷迪博士实验室有限公司 稳定的药物组合物
MX2018008300A (es) 2016-01-13 2018-09-21 Genmab As Formulacion para anticuerpo y conjugado de farmaco del mismo.
WO2017129685A1 (en) 2016-01-26 2017-08-03 Formycon Ag Liquid formulation of a vegf antagonist
MA46681A (fr) * 2016-01-28 2019-09-11 Janssen Biotech Inc Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
AR103622A1 (es) 2016-02-05 2017-05-24 Ucb Biopharma Sprl Formulación farmaceutica
EP3419663A1 (en) 2016-02-24 2019-01-02 Visterra, Inc. Formulations of antibody molecules to influenza virus
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
JP7155009B2 (ja) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
JP6992262B2 (ja) 2016-03-31 2022-02-15 東ソー株式会社 変性抗体測定試薬の製造方法
CN109310632A (zh) 2016-04-12 2019-02-05 封装技术私人有限公司 用于递送生物活性剂的可注射组合物
EP3443346B1 (en) 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
TWI826351B (zh) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US20210322537A1 (en) 2016-06-07 2021-10-21 Aridis Pharmaceuticals, Inc. Method For Preparation of Quick Dissolving Thin Films Containing Bioactive Material With Enhanced Thermal Stability
CN109415440B (zh) 2016-06-27 2022-12-06 莫佛塞斯公司 抗-cd19抗体制剂
PH12018502670B1 (en) 2016-06-30 2023-03-24 Celltrion Inc Stable liquid pharmaceutical preparation
CN115998858A (zh) 2016-07-05 2023-04-25 赛诺菲 抗体制剂
JP2019521156A (ja) 2016-07-19 2019-07-25 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
FR3056912B1 (fr) 2016-09-30 2019-12-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Procede d'inactivation virale d'une preparation d'anticorps monoclonaux
WO2018067987A1 (en) 2016-10-06 2018-04-12 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
IL310367A (en) 2016-10-07 2024-03-01 Regeneron Pharma A stable protein at room temperature that has been lyophilized
GEAP202315128A (en) 2016-12-23 2023-02-10 Serum Institute Of India Pvt Ltd Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
US10940185B2 (en) 2016-12-28 2021-03-09 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
WO2018122053A1 (en) 2016-12-29 2018-07-05 F. Hoffmann-La Roche Ag Anti-angiopoietin-2 antibody formulation
CN108261544B (zh) 2016-12-30 2023-05-05 江苏太平洋美诺克生物药业股份有限公司 稳定的包含cd147单克隆抗体的药物制剂
CN108261391B (zh) 2016-12-30 2022-03-01 江苏太平洋美诺克生物药业有限公司 稳定的包含cd147单克隆抗体的药物制剂
CN110167531B (zh) 2017-01-11 2025-06-03 赛特瑞恩股份有限公司 稳定的液体调配物
MY189536A (en) 2017-01-17 2022-02-16 Hoffmann La Roche Subcutaneous her2 antibody formulations
WO2018134184A1 (en) 2017-01-19 2018-07-26 Bayer Pharma Aktiengesellschaft Novel stable formulation for fxia antibodies
GB201703063D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
GB201703062D0 (en) 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
BR112019018022A2 (pt) 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
UA129583C2 (uk) 2017-03-06 2025-06-11 Мерк Патент Гмбх Водний фармацевтичний склад, який містить антитіло проти pd-l1 авелумаб
MA46988A1 (fr) 2017-03-16 2020-06-30 Lg Chemical Ltd Formulation liquide d'anticorps anti-tnf alpha
US20180289802A1 (en) 2017-03-29 2018-10-11 Celgene Corporation Formulations comprising pd-1 binding proteins and methods of making thereof
JPWO2018179138A1 (ja) 2017-03-29 2020-02-06 持田製薬株式会社 抗体含有液体製剤
TW201836637A (zh) 2017-03-29 2018-10-16 持田製藥股份有限公司 含有抗體之液體製劑
KR102692727B1 (ko) 2017-03-31 2024-08-08 메이지 세이카 파루마 가부시키가이샤 수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
HRP20240167T1 (hr) 2017-04-28 2024-04-26 Amgen Inc. Formulacije ljudskih anti-rankl protutijela i postupci njihove upotrebe
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
AU2018300687A1 (en) 2017-07-10 2019-12-19 Bayer Pharma Aktiengesellschaft Prolactin receptor antibody for male and female pattern hair loss
CN107400164A (zh) 2017-07-18 2017-11-28 中山和芯生物技术有限公司 一种含蔗糖的生物制品稳定剂及其制备方法和应用
WO2019018640A1 (en) 2017-07-21 2019-01-24 Novartis Ag POSOLOGICAL REGIMES FOR ANTI-GITREN ANTIBODIES AND USES THEREOF
WO2019023392A1 (en) 2017-07-25 2019-01-31 Elektrofi, Inc. FORMATION OF PARTICLES COMPRISING AGENTS
CA3069392A1 (en) 2017-07-27 2019-01-31 Jiangsu Hengrui Medicine Co., Ltd. Sost antibody pharmaceutical composition and uses thereof
JP7407699B2 (ja) 2017-07-28 2024-01-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗体製剤
CA3073185A1 (en) 2017-08-15 2019-02-21 Progenity, Inc. Treatment of inflammatory disease using ingestible device to release immune modulator
KR20200044044A (ko) 2017-08-23 2020-04-28 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 제제 및 그 동결 건조 방법
WO2019050780A1 (en) 2017-09-05 2019-03-14 Merck Sharp & Dohme Corp. COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
MA50670A (fr) 2017-09-29 2020-08-05 Janssen Biotech Inc Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
JP7170983B2 (ja) 2017-10-13 2022-11-15 国立大学法人大阪大学 改善された保存安定性を有するタンパク質含有液体製剤およびその製造方法
CN109745559A (zh) 2017-11-01 2019-05-14 三生国健药业（上海）股份有限公司 抗人il-17a的单克隆抗体的液体制剂
GB201718888D0 (en) 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
AU2018375356A1 (en) 2017-11-29 2020-05-14 Neotope Neuroscience Limited Lyophilized formulation of a monoclonal antibody against transthyretin
MX2020005630A (es) 2017-11-30 2020-08-20 Bio Thera Solutions Ltd Formulacion liquida de anticuerpos humanizados para el tratamiento de enfermedades relacionadas con il-6.
CA3085656A1 (en) 2017-12-22 2019-06-27 Jiangsu Hengrui Medicine Co., Ltd. Lag-3 antibody pharmaceutical composition and use thereof
MX2020008219A (es) 2018-02-08 2020-10-22 Amgen Inc Formulacion farmaceutica de ph bajo.
IL277095B2 (en) 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
US11427639B2 (en) 2018-04-02 2022-08-30 Richter Gedeon Nyrt. Antibody-containing aqueous formulation and use thereof
WO2019193204A1 (en) 2018-04-06 2019-10-10 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
EP3774904A1 (en) 2018-04-10 2021-02-17 Genmab A/S Axl-specific antibodies for cancer treatment
EP3552631A1 (en) 2018-04-10 2019-10-16 Inatherys Antibody-drug conjugates and their uses for the treatment of cancer
AU2019256289A1 (en) 2018-04-17 2020-11-12 Outlook Therapeutics, Inc. Buffered formulations of bevacizumab for use of treating diseases
WO2019206987A1 (en) 2018-04-25 2019-10-31 Medimmune Limited Formulations of human anti-pd-l1 antibodies
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
SG11202011170YA (en) 2018-05-14 2020-12-30 Medimmune Ltd Antibodies against lif and dosage forms thereof
CN110538321B (zh) 2018-05-29 2023-03-10 江苏恒瑞医药股份有限公司 一种cd47抗体药物组合物及其用途
JP7458998B2 (ja) 2018-06-01 2024-04-01 ラクテン・メディカル，インコーポレイテッド フタロシアニン色素コンジュゲート組成物
WO2019236435A1 (en) 2018-06-07 2019-12-12 Merck Sharp & Dohme Corp. Lyosphere critical reagent kit
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019245373A1 (en) 2018-06-22 2019-12-26 Bioralix B.V. Formulations of biological polymers for oral administration
US11738068B2 (en) 2018-06-25 2023-08-29 Jcr Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
TW202011995A (zh) 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
EA202190189A1 (ru) 2018-07-05 2021-04-16 Ханчжоу Дэк Биотек Ко., Лтд Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты
EP3823594B1 (en) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Liquid antibody formulation
KR102934808B1 (ko) 2018-07-19 2026-03-05 (주)셀트리온 안정한 액체 약제학적 제제
US11396542B2 (en) 2018-08-21 2022-07-26 Synkrino Biotherapeutics, Inc. Astrotactin1-based compositions and pharmaceutical formulations
WO2020053301A1 (en) 2018-09-11 2020-03-19 Ichnos Sciences S.A. Compositions comprising a bispecific antibody, bufffer and one or more stabilizing agents
EP3849518B1 (en) 2018-09-13 2026-03-18 F. Hoffmann-La Roche AG Csf-1r antibody formulation
UA130250C2 (uk) 2018-10-05 2025-12-31 Файв Прайм Терапьютикс, Інк. Рідкий фармацевтичний склад та композиція на основі антитіла до fgfr2
MY205764A (en) 2018-10-10 2024-11-12 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
MY195368A (en) 2018-10-12 2023-01-16 Hangzhou Dac Biotech Co Ltd A Conjugation Linker Containing 2,3-Diaminosuccinyl Group
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
WO2020087003A1 (en) 2018-10-26 2020-04-30 Amgen Inc. Formulations comprising a tris buffer and a protein
SG11202103064YA (en) 2018-10-29 2021-05-28 Hoffmann La Roche Antibody formulation
CA3117245A1 (en) 2018-10-31 2020-05-07 Richter Gedeon Nyrt. Aqueous pharmaceutical formulations
AU2019375014A1 (en) 2018-11-06 2021-05-27 Genmab A/S Antibody formulation
WO2020097141A1 (en) 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
WO2020106948A1 (en) 2018-11-21 2020-05-28 Regeneron Pharmaceuticals, Inc. High concentration protein formulation
US12257340B2 (en) 2018-12-03 2025-03-25 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
IL317328A (en) 2018-12-14 2025-01-01 Morphosys Ag Antibody formulations
PE20211707A1 (es) 2019-01-08 2021-09-01 H Lundbeck As Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp
EP3914689A2 (en) 2019-01-25 2021-12-01 SiO2 Medical Products, Inc. Common contact surfaces for use in the manufacture, packaging, delivery, and assessment of biopharmaceutical products
PH12021551776A1 (en) 2019-01-31 2022-05-23 Hangzhou Dac Biotech Co Ltd A conjugate of an amanita toxin with branched linkers
CN113365609A (zh) 2019-01-31 2021-09-07 伊勒卓菲公司 颗粒形成和形态
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
TW202519263A (zh) 2019-03-21 2025-05-16 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
KR102660249B1 (ko) 2019-03-26 2024-04-25 레메젠 코, 리미티드 항-her2 항체 약물 접합체 약학 제제
AU2020254582B2 (en) 2019-04-01 2025-12-18 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
WO2020202106A1 (en) 2019-04-04 2020-10-08 Janssen Biotech, Inc. Method of administration of an anti-ifn-alpha/-omega antibody
UA130580C2 (uk) 2019-04-18 2026-03-25 Момента Фармасьютікалз, Інк. Сіалілований глікопротеїн
EP4631523A3 (en) 2019-05-01 2025-12-31 Novo Nordisk A/S ANTI-IL-6 ANTIBODY FORMULATION
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
WO2020233534A1 (zh) 2019-05-17 2020-11-26 百奥泰生物制药股份有限公司 抗体-药物偶联物制剂、制备方法及应用
JP7784898B2 (ja) 2019-05-24 2025-12-12 サノフイ 全身性硬化症を治療するための方法
AU2020282792B2 (en) 2019-05-28 2025-12-04 Banner Health ApoE antibodies, fusion proteins and uses thereof
WO2020247572A1 (en) 2019-06-05 2020-12-10 Seattle Genetics, Inc. Masked antibody formulations
CN110124030A (zh) 2019-06-10 2019-08-16 通化东宝生物科技有限公司 一种苏金单抗注射液及其制备方法
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN114245737A (zh) 2019-06-11 2022-03-25 司斐股份有限公司 微乳剂组合物
KR20220024914A (ko) 2019-06-24 2022-03-03 항저우 디에이씨 바이오테크 씨오, 엘티디 분지형 링커를 사용한 세포독성제 대 세포 결합 분자의 접합체
EP3766481A1 (en) 2019-07-19 2021-01-20 Ichnos Sciences SA Liquid antibody formulation
WO2021013689A1 (en) 2019-07-19 2021-01-28 Ichnos Sciences SA Lyophilized antibody formulation
CN112805566A (zh) 2019-07-29 2021-05-14 上海谷森医药有限公司 用于吸入治疗肺癌的抗体类药物制剂
WO2021050953A1 (en) 2019-09-13 2021-03-18 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
CA3155108A1 (en) 2019-09-20 2021-03-25 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (il-17) antagonists
CN110585430B (zh) 2019-09-29 2023-09-08 华博生物医药技术（上海）有限公司 一种人源化抗人il-17a单克隆抗体的药物组合物
WO2021067775A1 (en) 2019-10-02 2021-04-08 Alamab Therapeutics, Inc. Anto-connexin antibody formulations
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
CN112891531B (zh) 2020-06-19 2021-10-08 北京东方百泰生物科技股份有限公司 一种抗il-17ra单克隆抗体的注射制剂

Also Published As

Publication number Publication date
US20200262911A1 (en) 2020-08-20
EP3927729A1 (en) 2021-12-29
NZ778977A (en) 2025-06-27
AU2020225202A1 (en) 2021-08-12
MX2021009851A (es) 2021-09-10
UA128098C2 (uk) 2024-04-03
US11634485B2 (en) 2023-04-25
KR102735988B9 (ko) 2025-02-13
KR20210114989A (ko) 2021-09-24
WO2020172002A1 (en) 2020-08-27
SG11202108627SA (en) 2021-09-29
AU2023251529B2 (en) 2025-09-04
IL285134A (en) 2021-09-30
CN120241997A (zh) 2025-07-04
CO2021010697A2 (es) 2021-10-29
CL2021002182A1 (es) 2022-03-18
MA55033A (fr) 2021-12-29
BR112021015034A2 (pt) 2021-10-05
JP7266108B2 (ja) 2023-04-27
JP7551822B2 (ja) 2024-09-17
KR102735988B1 (ko) 2024-12-03
US20230183334A1 (en) 2023-06-15
JP2022520857A (ja) 2022-04-01
JP2023089190A (ja) 2023-06-27
AU2023251529A1 (en) 2024-01-18
CA3129901A1 (en) 2020-08-27
PH12021551916A1 (en) 2022-05-23
CN113474360B (zh) 2025-01-07
CR20210435A (es) 2021-09-20
JOP20210229A1 (ar) 2023-01-30
PE20212185A1 (es) 2021-11-11
DOP2021000170A (es) 2021-09-30
AU2020225202B2 (en) 2023-10-26
EP3927729A4 (en) 2023-10-11
CN113474360A (zh) 2021-10-01

Similar Documents

Publication Publication Date Title
DOP2021000170A (es) Formulacion de anticuerpos terapeuticos
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
MX2020010881A (es) Construcciones de anticuerpos anti-ror.
CL2022001489A1 (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CR20160141A (es) Formulaciones de anticuerpos anti-pdl1
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
WO2018075692A3 (en) Antibody constructs
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
CO2017004714A2 (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
MX2021016050A (es) Formulaciones transdermicas.
CL2022001486A1 (es) Formulaciones de anticuerpos anti-pd-l1.
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
JOP20190183A1 (ar) معدِلات مستقبلات الاستروجين
CL2022001546A1 (es) Formulaciones líquidas de tasimelteón y métodos para su uso
MX394644B (es) Excipiente a base de proteínas para ingredientes farmacéuticos activos.
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
MX2021005910A (es) Formulacion de proteina de alta concentracion.
IL284997A (en) Methods for making mixed allergen compositions
MX2021010207A (es) Formulacion farmaceutica de liberacion extendida.
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
CL2024004013A1 (es) Formulación farmacéutica que comprende un anticuerpo anti-il-23p19; y su uso.
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
IL283405A (en) Formulations, methods, kits and dosage forms to improve the stability of an active medicinal component
BR112022009587A2 (pt) Anticorpo anti-pcsk9 e uso do mesmo